A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|DRUG: Atezolizumab Placebo|DRUG: Paclitaxel
Sponsor: Hoffmann-La Roche